Payment overview · 2025
General Payments
$1,128.24
77 reported records · 15 companies
Healthcare provider profile · identity verified
Gregory Lee Winger, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ST GEORGE, UT · NPI 1235661745
Verified facts
What the public records show
CMS Open Payments records show Gregory Lee Winger, M.D. received $1,128.24 in general payments during 2025 across 77 reported records.
ABBVIE INC. accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $435.31 | 38.6% | 26 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.63 | 15.2% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $103.33 | 9.2% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.61 | 7.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.38 | 5.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $56.34 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.48 | 3.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.88 | 3.0% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $32.72 | 2.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $27.26 | 2.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.83 | 2.1% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $18.47 | 1.6% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $18.00 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.60 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,128.24 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $313.19 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $301.65 | 17 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $150.10 | 22 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $150.10 | 22 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.39 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $79.61 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.34 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.34 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.34 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $41.48 | 2 | 2025 |
Source payment records
|
|||||
| Artisan Normalized: artisan |
Device | Boston Scientific Corporation | $39.39 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $32.72 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $23.83 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.53 | 2 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 674 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 595 | 172 |
| Losartan Potassium | Losartan Potassium | 423 | 121 |
| Omeprazole | Omeprazole | 397 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 117 |
| Lisinopril | Lisinopril | 364 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 99 |
| Trazodone Hcl | Trazodone Hcl | 279 | 89 |
| Metformin Hcl | Metformin Hcl | 278 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 68 |
| Simvastatin | Simvastatin | 211 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 65 |
| Gabapentin | Gabapentin | 170 | 63 |
| Celecoxib | Celecoxib | 165 | 58 |
| Montelukast Sodium | Montelukast Sodium | 161 | 61 |
| Bupropion Xl | Bupropion Hcl | 158 | 52 |
| Metformin Hcl Er | Metformin Hcl | 150 | 43 |
| Meloxicam | Meloxicam | 145 | 53 |
| Famotidine | Famotidine | 144 | 55 |
| Eliquis | Apixaban | 142 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 37 |
| Alendronate Sodium | Alendronate Sodium | 124 | 34 |
| Azithromycin | Azithromycin | 120 | 107 |
| Potassium Chloride | Potassium Chloride | 111 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 30 |
| Finasteride | Finasteride | 100 | 34 |
| Sertraline Hcl | Sertraline Hcl | 98 | 28 |
| Temazepam | Temazepam | 97 | 19 |
| Tramadol Hcl | Tramadol Hcl | 96 | 42 |
| Carvedilol | Carvedilol | 93 | 30 |
| Allopurinol | Allopurinol | 92 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 42 |
| Furosemide | Furosemide | 79 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 23 |
| Methylprednisolone | Methylprednisolone | 76 | 71 |
| Donepezil Hcl | Donepezil Hcl | 75 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 17 |
| Cephalexin | Cephalexin | 56 | 46 |
| Prednisone | Prednisone | 53 | 42 |
| Alprazolam | Alprazolam | 49 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 14 |
| Spironolactone | Spironolactone | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 16 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Lorazepam | Lorazepam | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Atenolol | Atenolol | 42 | 12 |
| Estradiol | Estradiol | 42 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Synthroid | Levothyroxine Sodium | 41 | 12 |
| Ondansetron Odt | Ondansetron | 40 | 25 |
| Glipizide | Glipizide | 39 | 16 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 30 |
| Lovastatin | Lovastatin | 37 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 33 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 29 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Valsartan | Valsartan | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Linzess | Linaclotide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Griseofulvin | Griseofulvin, Microsize | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,128.24 · 77 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Artisan, BEYFORTUS, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, KISUNLA, KRYSTEXXA, MOUNJARO, NEMLUVIO, NEXPLANON, NURTEC ODT, PAXLOVID, PREVNAR 20, QULIPTA, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, WATCHMAN FLX, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error